Effects of Schisandra sphenanthera extract on the pharmacokinetics of midazolam in healthy volunteers

British Journal of Clinical Pharmacology

Volumn 67, Issue 5, 2009, Pages 541-546

  Xin, Hua Wen ^a   Wu, Xiao Chun ^a   Li, Qing ^a   Yu, Ai Rong ^a   Xiong, Lei ^a  

^a WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

Author keywords

CYP3A; Healthy volunteers; Hydroxymidazolam; Midazolam; Pharmacokinetics; Schisandra sphenanthera extract

Indexed keywords

1' HYDROXY MIDAZOLAM; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; MIDAZOLAM; PLANT EXTRACT; SCHISANDRA SPHENANTHERA EXTRACT; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONFIDENCE INTERVAL; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DISPOSITION; DRUG EFFECT; DRUG METABOLISM; DRUG SENSITIVITY; ENZYME ACTIVITY; HALF LIFE TIME; HERB DRUG INTERACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NORMAL HUMAN; PARAMETER; PRIORITY JOURNAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; VOLUNTEER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HALF-LIFE; HUMANS; MALE; MIDAZOLAM; MIDDLE AGED; PLANT EXTRACTS; SCHISANDRA; YOUNG ADULT;

EID: 65349149399     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03383.x     Document Type: Article

References (23)

1. Madgula VL, Avula B, Choi YW, Pullela SV, Khan IA, Walker LA, Khan SI. Transport of Schisandra chinensis extract and its biologically-active constituents across Caco-2 cell monolayers - an in-vitro model of intestinal transport. J Pharm Pharmacol 2008 60 : 363 70.
2. Wan CK, Zhu GY, Shen XL, Chattopadhyay A, Dey S, Fong WF. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells. Biochem Pharmacol 2006 72 : 824 37.
3. Sun M, Xu X, Lu Q, Pan Q, Hu X. Schisandrin B: a dual inhibitor of P-glycoprotein and multidrug resistance-associated protein 1. Cancer Lett 2007 246 : 300 7.
4. Iwata H, Tezuka Y, Kadota S, Hiratsuka A, Watabe T. Identification and characterization of potent CYP3A4 inhibitors in Schisandra fruit extract. Drug Metab Dispos 2004 32 : 1351 8.
5. Bowman LJ, Brennan DC. The role of tacrolimus in renal transplantation. Expert Opin Pharmacother 2008 9 : 635 43.
6. Patel JK, Kobashigawa JA. Tacrolimus in heart transplant recipients: an overview. BioDrugs 2007 21 : 139 43.
7. Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet 2007 22 : 328 35.
8. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993 268 : 6077 80.
9. Xin HW, Wu XC, Li Q, Yu AR, Zhu M, Shen Y, Su D, Xiong L. Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers. Br J Clin Pharmacol 2007 64 : 469 75.
10. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994 4 : 171 84.
11. Rogers JF, Rocci ML Jr., Haughey DB, Bertino JS Jr. An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity. Clin Pharmacol Ther 2003 73 : 153 8.
12. Lee JI, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW, Fyre RF. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3 A phenotyping. Clin Pharmacol Ther 2002 72 : 718 28.
13. Kim JS, Nafziger AN, Tsunoda SM, Rocci ML Jr., Wilkinson GR, Greenblatt DJ, Bertino JS Jr. Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques. J Clin Pharmacol 2002 42 : 376 82.
14. Yue QY, Bergquist C, Gerden B. Safety of St. John's wort (Hypericum perforatum). Lancet 2000 355 : 576 7.
15. Von Moltke LL, Weemholff JL, Bedir E, Khan IA, Harmatz JS, Goldman P, Greenblatt DJ. Inhibition of human cytochrome P450 by components of Ginkgo biloba. J Pharm Pharmacol 2004 56 : 1039 44.
16. Yale SH, Glurich I. Analysis of inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on metabolic activity of cytochrome P450 3A4,2D6, and 2C9. J Altern Complement Med 2005 75 : 433 9.
17. Matsuda K, Nishimura Y, Kurata N, Iwase M, Yasuhara H. Effects of continuous ingestion of herbal teas on intestinal CYP3A in the rat. J Pharmacol Sci 2007 103 : 214 21.
18. Kupferschmidt HH, Ha HR, Ziegler WH, Meier PJ, Krähenbühl S. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995 58 : 20 8.
19. Nies AS, Shand DG, Willkinsin GR. Altered hepatic blood flow and drug disposition. Clin Pharmacokinet 1976 1 : 135 55.
20. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, Raisys VA, Marsh CL, McVicar JP, Barr DM. Use of midazolam as a human cytochrome P4503A probe: I: in vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994 271 : 549 56.
21. Zhu B, Ou-Yang DS, Cheng ZN, Huang SL, Zhou HH. Single plasma sampling to predict oral clearance of CYP3A probe midazolam. Acta Pharmacol Sin 2001 22 : 634 8.
22. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999 16 : 408 14.
23. Wandel C, Bocker RH, Bohrer H, deVries JX, Hofmann W, Walter K, Kleingeist B, Neff S, Ding R, Walter-Sack I, Martin E. Relationship between hepatic cytochrome P450 3A content and activity and the disposition of midazolam administered orally. Drug Metab Dispos 1998 26 : 110 4.